Nihon Kohden Corporation announced today that Nihon Kohden Middle East (NKME), one of its subsidiaries, will establish a hematology analyzer reagent factory.
1. Purpose
Nihon Kohden established NKME in 2012 and has strengthened its business structure in the Middle East and Africa. In the Middle East and Africa, the medical infrastructure has been developing in accordance with economic growth and the demand for blood testing is growing year by year. Nihon Kohden Firenze, one of its subsidiaries, has provided reagents to these markets. By establishing the new factory, Nihon Kohden will be able to respond quickly and flexibly to this growing demand. The Company also aims to establish a production system which will enable stable supply of genuine high quality reagents in a timely manner. The new factory will start operations in 2020.
Nihon Kohden’s mid-term business plan, TRANSFORM 2020, calls for the Company to conduct strategic business expansion to meet medical needs in high growth emerging markets. The Company will continue to expand its international business by strengthening its local business structures and providing high quality advanced medical devices.
2. Outline of reagent factory in Dubai
| Address | DAFZA (Dubai Airport Freezone Authority) Industrial Park, Dubai, United Arab Emirates |
|---|---|
| Line of business | Manufacture and sales of hematology analyzer reagents |
| Total investments |
About 0.25 billion yen (For production equipment only. The building will be leased.) |
| Employees | 13 (planned) |
3. Effect on operating results of Nihon Kohden
The effect of establishment of the new factory on the consolidated results for the fiscal year ending March 31, 2020 will be minor.
